|
Jul 1
|
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
|
|
Jun 30
|
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
|
|
Jun 20
|
Rakovina Therapeutics Announces Share Consolidation Effective Date
|
|
Jun 18
|
Exploring Global High Growth Tech Stocks with Promising Potential
|
|
Jun 6
|
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
|
|
Jun 2
|
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
|
|
May 28
|
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
|
|
Apr 22
|
Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery
|
|
Mar 12
|
Rakovina's AI-driven Anti-Cancer Compounds in Pre-clinical Testing
|
|
Mar 12
|
Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing
|
|
Jul 27
|
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
|
|
Jun 20
|
Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting
|